EUROIMMUN Logo
Find
X

What are you looking for?

Filter for products in our complete portfolio

Product finder

Worldwide
X
EUROIMMUN worldwide

This website provides an overview of the business activities and products of EUROIMMUN AG worldwide. Not all products are registered and approved in all countries or regions. Please contact your country representative for product availability and information

EUROIMMUN branches

Choose your country

Europe

North America

South & Central America

Asia

Middle East & Africa

EUROIMMUN Logo
Product finder

Alzheimer’s disease

Clinical information

With 60 to 70%, Alzheimer's disease is the most frequent cause of dementia in old age. Its prevalence doubles about every five years from the age of 65. 30% of over 90 year-olds suffer from this disease. Alzheimer's disease is a progressive and irreversible deterioration of cognitive abilities. The disease course is divided into three consecutive phases, which are the preclinical stage, the MCI (mild cognitive impairment) stage and dementia. In patients with Alzheimer's disease, proteins are accumulated in the brain, which is associated with the destruction of nerve cells.

Within the nerve cells (particularly in the cortical and limbic brain regions) accumulation of neurofibrillary tangles from hyperphosphorylated tau protein (pTau(181)) occurs. Tau is expressed in neurons, where it stabilises the microtubuli of the cytoskeleton. Incorrect phosphorylation of this protein leads to aggregation in the form of neurofibrils, which accumulate in the nerve cell bodies and interfere with the axonal transport.

Outside of the nerve cells, accumulation of senile plaques is observed, which mainly consist of beta-amyloids (Aβ). These are peptides that are produced by processing of the membrane-bound amyloid precursor protein (APP) and exist in various isoforms. In Alzheimer's disease the breakdown of these peptides is impaired, which leads to deposits of especially beta-amyloid (1-40) (Aβ1-40) and beta-amyloid (1-42) (Aβ1-42) in the form of plaques.

Diagnostics

Concentration of amyloid quotientDefinitive diagnosis of Alzheimer's disease is only possible post-mortem by means of histological examination of a brain tissue sample (detection of plaques and neurofibrillary tangles). The diagnosis of probable Alzheimer's disease can be made in the lifetime of a patient based on the clinical presence of dementia syndrome and the exclusion of possible reversible causes. Further information can be obtained by positron emission tomography (PET), which can now be used to visualise the specific neuropathological changes in living patients. Moreover, the determination of biomarkers in cerebrospinal fluid (CSF) has become established in Alzheimer's diagnostics. They are also able to indicate the disease with high reliability.

The CSF of patients who will develop Alzheimer's disease show significantly decreased concentrations of Aβ1-42as early as 5 to 10 years before the onset of cognitive changes. The concentrations of total tau and pTau(181), however, increase with progressing neurodegeneration and cognitive impairment. The amyloid quotient Aβ1-42/Aβ1-40 can be useful in the differentiation of Alzheimer's disease from vascular dementia (see figure). Calculation of this quotient also reduces the distorting influences of preclinical factors on the measured concentrations.

The results obtained with CSF-based neurochemical analyses should always be assessed in the context of all available diagnostic information.

 

Brochure: Diagnosing Alzheimer’s disease - A new generation of tests from EUROIMMUN

Preanalytics in dementia diagnostics

Recognising external influencing factors, optimising work processes

 

 Request brochure

Techniques

Method
Parameter
Substrate
ChLIA
Control set Beta-Amyloid (1-40) ChLIA
2 x 0.5 ml control 1/2
Details
ELISA
beta-amyloid (1-40)
determination in CSF
Details
ChLIA
Beta-Amyloid (1-40), determination in CSF
Antibody-coated magnetic particles
Details
ELISA
beta-amyloid (1-42)
determination in CSF
Details
ChLIA
Control set Beta-Amyloid (1-42) ChLIA
2 x 0.5 ml control 1/2
Details
ChLIA
Beta-Amyloid (1-42), determination in CSF
Antibody-coated magnetic particles
Details
ChLIA
Control set Total-tau ChLIA
2 x 0.5 ml control 1/2
Details
ELISA
total tau
determination in CSF
Details
ChLIA
Total-tau, determination in CSF
Antibody-coated magnetic particles
Details
ELISA
pTau(181)
determination in CSF
Details
ChLIA
Control set pTau(181) ChLIA
2 x 0.5 ml control 1/2
Details
ChLIA
pTau(181), determination in CSF
Antibody-coated magnetic particles
Details
Show all products
Back to top
Contact person on site
Please click on a country or enter yours
North America
South & Central America
Europe
Asia
Oceania
Middle East & Africa